Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Expected to Announce Quarterly Sales of $119.16 Million

Equities research analysts expect Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) to announce sales of $119.16 million for the current fiscal quarter, Zacks reports. Three analysts have issued estimates for Lexicon Pharmaceuticals’ earnings. The lowest sales estimate is $26.15 million and the highest is $167.71 million. Lexicon Pharmaceuticals reported sales of $294.45 million in the same quarter last year, which would suggest a negative year over year growth rate of 59.5%. The company is expected to announce its next quarterly earnings report on Thursday, November 5th.

On average, analysts expect that Lexicon Pharmaceuticals will report full-year sales of $147.82 million for the current fiscal year, with estimates ranging from $43.45 million to $184.87 million. For the next fiscal year, analysts expect that the business will report sales of $7.98 million, with estimates ranging from $590,000.00 to $15.37 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research firms that cover Lexicon Pharmaceuticals.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last announced its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported ($0.63) earnings per share for the quarter, missing the consensus estimate of ($0.61) by ($0.02). Lexicon Pharmaceuticals had a return on equity of 50.16% and a net margin of 12.26%. The firm had revenue of $9.16 million during the quarter, compared to analysts’ expectations of $8.70 million.

Several equities research analysts recently weighed in on the company. JPMorgan Chase & Co. assumed coverage on Lexicon Pharmaceuticals in a report on Wednesday. They issued an “underweight” rating for the company. ValuEngine raised Lexicon Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Friday, September 11th. Wedbush reissued a “buy” rating and issued a $3.00 price objective on shares of Lexicon Pharmaceuticals in a report on Monday, August 3rd. Finally, Zacks Investment Research raised Lexicon Pharmaceuticals from a “hold” rating to a “buy” rating and set a $2.00 target price for the company in a report on Saturday, June 20th. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating and three have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and an average price target of $2.37.

Hedge funds have recently bought and sold shares of the business. Investors Financial Group LLC purchased a new position in Lexicon Pharmaceuticals during the 2nd quarter valued at about $31,000. Diversified Trust Co purchased a new position in shares of Lexicon Pharmaceuticals during the second quarter worth about $35,000. Jane Street Group LLC purchased a new position in shares of Lexicon Pharmaceuticals during the second quarter worth about $36,000. ProShare Advisors LLC grew its holdings in shares of Lexicon Pharmaceuticals by 33.0% during the second quarter. ProShare Advisors LLC now owns 22,702 shares of the biopharmaceutical company’s stock worth $45,000 after purchasing an additional 5,629 shares in the last quarter. Finally, UBS Group AG grew its holdings in shares of Lexicon Pharmaceuticals by 63.2% during the second quarter. UBS Group AG now owns 26,891 shares of the biopharmaceutical company’s stock worth $54,000 after purchasing an additional 10,416 shares in the last quarter.

LXRX traded down $0.04 during trading hours on Tuesday, hitting $1.47. The stock had a trading volume of 437,582 shares, compared to its average volume of 1,179,828. The company’s fifty day simple moving average is $1.57 and its 200 day simple moving average is $1.84. Lexicon Pharmaceuticals has a 1 year low of $1.37 and a 1 year high of $5.33. The stock has a market cap of $157.45 million, a PE ratio of 7.74 and a beta of 1.38. The company has a quick ratio of 2.48, a current ratio of 2.52 and a debt-to-equity ratio of 4.28.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults.

Featured Article: What does a dividend yield signify to investors?

Get a free copy of the Zacks research report on Lexicon Pharmaceuticals (LXRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Lexicon Pharmaceuticals (NASDAQ:LXRX)

Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.